Core Viewpoint - Baixinan-B (02185) experienced a significant increase of over 52% in stock price, reaching HKD 9.22 with a trading volume of HKD 98.296 million, following the announcement of its Iberis RDN system receiving a 5-year healthcare qualification in France [1] Group 1: Product Development and Market Expansion - The Iberis RDN system has been granted a 5-year healthcare qualification by French authorities, with the potential for renewal, enhancing the clinical application support system in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Group 2: Clinical Success and Market Potential - In February, Baixinan's subsidiary, Shanghai Antong Medical, completed the first commercial procedure of the Iberis RDN system in Germany [1] - According to CITIC Securities, the RDN procedure shows significant and long-term effective blood pressure reduction, with a simple operation and low complication rates, indicating a broad long-term market potential [1] - The company's RDN products are advancing commercialization simultaneously in domestic and international markets, with a focus on the results of the first year of commercialization in 2025 [1]

Core Viewpoint - 百心安-B's stock surged over 52% following the announcement of its Iberis RDN system receiving a five-year healthcare qualification in France, indicating strong market potential and positive clinical developments [1] Company Developments - 百心安's Iberis RDN system has been granted a five-year healthcare qualification by French authorities, with the possibility of renewal, enhancing its clinical application support in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Market Performance - As of the latest report, 百心安-B's stock price reached 9.22 HKD, with a trading volume of 98.2961 million HKD, reflecting strong investor interest [1] - 中信建投 highlighted the significant and long-term effectiveness of RDN in lowering blood pressure, along with its simple procedure and low complication rates, suggesting a broad long-term market potential [1] Commercialization Progress - 百心安's Iberis RDN system completed its first commercial procedure in Germany in February this year, marking a significant milestone in its commercialization efforts [1] - The company is advancing the commercialization of its RDN products both domestically and internationally, with a focus on the results of its first year of commercialization in 2025 [1]